News

The milestone payment extends the exclusive use of Elast-Eon 2 in the field of cardiac pacing, ICD (implantable cardiac defibrillator) and cardiac monitoring leads into perpetuity. One further

This Phase I dose-finding study provided clear evidence of the effectiveness of Ardana’s cream in the transdermal delivery of testosterone in females. The double-blind, randomised, placebo-controlled study involved

As part of the optimization phase of development, AGI completed a number of studies in healthy human volunteers. These studies characterized the drug release profile, the pharmacokinetics of

This is the second of two safety and efficacy trials to be conducted under conditions set forth in a special protocol assessment (SPA) agreement with the FDA. The

Arpida has requested a priority designation for the review of the new drug application (NDA). The iclaprim NDA contains data from 15 clinical studies, including two adequate and

The aim of this agreement is to secure commercial supplies of an appropriate scale to ensure the successful commercial launch of naproxcinod. The filing of a new drug

In this study, all doses of ciclesonide HFA (75mcg, 150mcg and 300mcg once-daily) met the primary efficacy endpoint and demonstrated a statistically significant reduction in 24-hour total nasal

The interim data from this ongoing Phase I/II clinical trial shows that tgAAC94 is well-tolerated at the highest dose tested in the trial and demonstrate that a higher

This payment is triggered by Pharmacopeia’s completion of certain early discovery activities established under its agreement with GlaxoSmithKline (GSK). Pharmacopeia is entitled to success-based milestone payments totaling up